Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.
Journal
European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848
Informations de publication
Date de publication:
21 04 2022
21 04 2022
Historique:
received:
25
11
2021
accepted:
23
03
2022
pubmed:
24
3
2022
medline:
26
4
2022
entrez:
23
3
2022
Statut:
epublish
Résumé
Growth hormone (GH) has been used for over 35 years, and its safety and efficacy has been studied extensively. Experimental studies showing the permissive role of GH/insulin-like growth factor 1 (IGF-I) in carcinogenesis have raised concerns regarding the safety of GH replacement in children and adults who have received treatment for cancer and those with intracranial and pituitary tumours. A consensus statement was produced to guide decision-making on GH replacement in children and adult survivors of cancer, in those treated for intracranial and pituitary tumours and in patients with increased cancer risk. With the support of the European Society of Endocrinology, the Growth Hormone Research Society convened a Workshop, where 55 international key opinion leaders representing 10 professional societies were invited to participate. This consensus statement utilized: (1) a critical review paper produced before the Workshop, (2) five plenary talks, (3) evidence-based comments from four breakout groups, and (4) discussions during report-back sessions. Current evidence reviewed from the proceedings from the Workshop does not support an association between GH replacement and primary tumour or cancer recurrence. The effect of GH replacement on secondary neoplasia risk is minor compared to host- and tumour treatment-related factors. There is no evidence for an association between GH replacement and increased mortality from cancer amongst GH-deficient childhood cancer survivors. Patients with pituitary tumour or craniopharyngioma remnants receiving GH replacement do not need to be treated or monitored differently than those not receiving GH. GH replacement might be considered in GH-deficient adult cancer survivors in remission after careful individual risk/benefit analysis. In children with cancer predisposition syndromes, GH treatment is generally contraindicated but may be considered cautiously in select patients.
Identifiants
pubmed: 35319491
doi: 10.1530/EJE-21-1186
pmc: PMC9066587
doi:
Substances chimiques
Human Growth Hormone
12629-01-5
Insulin-Like Growth Factor I
67763-96-6
Growth Hormone
9002-72-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
P35-P52Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Endocrinology. 2007 Oct;148(10):4536-44
pubmed: 17584969
Arch Endocrinol Metab. 2019 Nov-Dec;63(6):568-575
pubmed: 31939481
J Clin Endocrinol Metab. 2014 Dec;99(12):4712-9
pubmed: 25210883
J Clin Endocrinol Metab. 2006 Sep;91(9):3494-8
pubmed: 16822820
J Clin Endocrinol Metab. 2011 Aug;96(8):2330-40
pubmed: 21613351
Nature. 1985 Feb 28-Mar 6;313(6005):745-7
pubmed: 3883191
J Neurosurg Pediatr. 2016 Oct;18(4):408-412
pubmed: 27286443
Cancers (Basel). 2020 Dec 04;12(12):
pubmed: 33291663
Eur J Endocrinol. 2015 Jun;172(6):779-90
pubmed: 25810462
Expert Opin Drug Saf. 2020 Dec;19(12):1539-1548
pubmed: 33089723
World Neurosurg. 2020 Jun;138:89-92
pubmed: 32059964
J Clin Oncol. 2002 Jul 1;20(13):2959-64
pubmed: 12089225
Neuro Oncol. 2019 Feb 19;21(3):392-403
pubmed: 30099534
J Clin Oncol. 2017 Jul 10;35(20):2288-2298
pubmed: 28530852
Science. 1963 May 31;140(3570):987-8
pubmed: 13975313
Crit Rev Oncol Hematol. 2013 Sep;87(3):201-23
pubmed: 23434537
Neurosurgery. 2010 Sep;67(3):617-25; discussion 625
pubmed: 20647974
Trends Endocrinol Metab. 2017 Aug;28(8):587-596
pubmed: 28622965
Cancer Res. 1986 Mar;46(3):1015-29
pubmed: 3002607
J Clin Endocrinol Metab. 2011 Jun;96(6):1587-609
pubmed: 21602453
Cancer Med. 2016 Nov;5(11):3353-3367
pubmed: 27734632
J Clin Oncol. 2001 Jan 15;19(2):480-7
pubmed: 11208842
Recent Results Cancer Res. 2014;202:39-46
pubmed: 24531775
J Clin Endocrinol Metab. 2018 Aug 1;103(8):2761-2784
pubmed: 29982476
Clin Dysmorphol. 2012 Oct;21(4):212-214
pubmed: 22664660
Horm Res. 1998;49(2):91-7
pubmed: 9485178
Growth Horm IGF Res. 2018 Aug;41:71-74
pubmed: 29571594
J Clin Endocrinol Metab. 2017 May 1;102(5):1661-1672
pubmed: 28187225
Arch Dis Child. 1987 May;62(5):461-4
pubmed: 3606177
Horm Res Paediatr. 2015;83(3):157-66
pubmed: 25503994
Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):133-141
pubmed: 33033142
PLoS One. 2020 Dec 3;15(12):e0242358
pubmed: 33270637
Blood. 2019 Mar 7;133(10):1130-1139
pubmed: 30573632
Eur J Endocrinol. 2016 Feb;174(2):P1-9
pubmed: 26563978
Clin Endocrinol (Oxf). 2009 Mar;70(3):435-8
pubmed: 19236640
Acta Paediatr. 2006 Oct;95(10):1284-90
pubmed: 16982503
Eur J Endocrinol. 2017 May;176(5):R217-R233
pubmed: 28193628
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):293-301
pubmed: 27913494
Endocr Connect. 2021 Jan;10(1):76-83
pubmed: 33320108
Pituitary. 2021 Oct;24(5):810-827
pubmed: 34304361
J Clin Endocrinol Metab. 2001 Nov;86(11):5245-51
pubmed: 11701685
Eur J Endocrinol. 2018 May;178(5):R155-R181
pubmed: 29459441
Pituitary. 2017 Feb;20(1):70-75
pubmed: 27631334
J Clin Oncol. 2015 Feb 10;33(5):492-500
pubmed: 25559807
Eur J Endocrinol. 2005 Feb;152(2):165-70
pubmed: 15745921
J Clin Endocrinol Metab. 2013 Oct;98(10):3932-8
pubmed: 23928670
J Clin Endocrinol Metab. 2009 Nov;94(11):4195-204
pubmed: 19837937
Pituitary. 2012 Sep;15(3):301-10
pubmed: 22271255
Endocr Connect. 2018 Mar;7(3):R126-R134
pubmed: 29483159
J Clin Endocrinol Metab. 2019 Mar 1;104(3):658-664
pubmed: 30137467
J Clin Endocrinol Metab. 1999 Apr;84(4):1324-8
pubmed: 10199773
Gen Comp Endocrinol. 2015 Sep 1;220:103-11
pubmed: 25448258
Am J Dis Child. 1985 Apr;139(4):347-50
pubmed: 3976624
JCI Insight. 2019 Feb 7;4(3):
pubmed: 30728323
Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):E3250-9
pubmed: 27226307
Am J Clin Nutr. 2012 Aug;96(2):345-55
pubmed: 22760570
Eur J Endocrinol. 2020 Oct;183(4):471-480
pubmed: 32738133
J Clin Endocrinol Metab. 2010 Aug;95(8):3726-35
pubmed: 20484480
Endocr Rev. 2019 Apr 1;40(2):558-574
pubmed: 30500870
Pediatr Blood Cancer. 2013 Jul;60(7):1148-53
pubmed: 23322583
Eur J Endocrinol. 2016 Oct;175(4):R147-56
pubmed: 27089890
Endocr Pract. 2019 Nov;25(11):1191-1232
pubmed: 31760824
Cancer Res. 2010 Jun 1;70(11):4453-9
pubmed: 20460509
Clin Endocrinol (Oxf). 1999 Jun;50(6):703-13
pubmed: 10468941
Eur J Endocrinol. 2016 Jun;174(6):C1-8
pubmed: 27009113
Int J Cancer. 2014 Jun 1;134(11):2683-90
pubmed: 24248481
J Clin Endocrinol Metab. 2013 Mar;98(3):980-8
pubmed: 23345098
Eur J Endocrinol. 2007 Dec;157(6):695-700
pubmed: 18057375
Signal Transduct Target Ther. 2019 Feb 8;4:3
pubmed: 30775002
J Clin Oncol. 2019 Feb 20;37(6):453-460
pubmed: 30526229
Front Endocrinol (Lausanne). 2019 Jul 31;10:525
pubmed: 31417499
J Clin Neurosci. 2013 Jan;20(1):153-7
pubmed: 23117141
Clin Endocrinol (Oxf). 2006 May;64(5):556-60
pubmed: 16649976
Eur J Endocrinol. 2012 Jun;166(6):1061-8
pubmed: 22457235
Endocr Relat Cancer. 2006 Jun;13(2):593-605
pubmed: 16728585
Eur J Endocrinol. 2011 Apr;164(4):485-9
pubmed: 21292919
J Clin Endocrinol Metab. 2000 Oct;85(10):3693-9
pubmed: 11061526
BMJ. 1992 Jun 20;304(6842):1601-5
pubmed: 1628087
Endocr Pract. 2009 Sep-Oct;15 Suppl 2:1-29
pubmed: 20228036
BMC Endocr Disord. 2020 Apr 29;20(1):55
pubmed: 32349731
J Intern Med. 2021 Dec;290(6):1180-1193
pubmed: 34605087
J Clin Endocrinol Metab. 2019 Dec 1;104(12):6101-6115
pubmed: 31373627
J Clin Endocrinol Metab. 2001 Feb;86(2):663-8
pubmed: 11158028
Endocrinology. 2021 Apr 1;162(4):
pubmed: 33475144
Sci Transl Med. 2011 Feb 16;3(70):70ra13
pubmed: 21325617
Pituitary. 2016 Jun;19(3):332-41
pubmed: 26897383
Horm Cancer. 2017 Jun;8(3):143-156
pubmed: 28293855
Ann Hum Biol. 2011 Mar;38(2):194-202
pubmed: 20731527
J Clin Endocrinol Metab. 2020 May 1;105(5):
pubmed: 32112101
Br J Cancer. 2015 Apr 14;112(8):1392-7
pubmed: 25742478
J Neurooncol. 2021 Jun;153(2):239-249
pubmed: 33886110
J Clin Endocrinol Metab. 2002 Feb;87(2):477-85
pubmed: 11836272
N Engl J Med. 1989 Dec 28;321(26):1797-803
pubmed: 2687691
Nat Rev Endocrinol. 2011 Jan;7(1):11-24
pubmed: 20956999
Lancet Oncol. 2013 Jul;14(8):e321-8
pubmed: 23816298
Pediatr Blood Cancer. 2016 Aug;63(8):1332-8
pubmed: 27100618
J Clin Endocrinol Metab. 2021 Nov 19;106(12):3487-3496
pubmed: 34343297
J Clin Endocrinol Metab. 2015 Jun;100(6):2192-203
pubmed: 25839904
Eur J Endocrinol. 2020 Oct;183(4):D1-D13
pubmed: 32698136
Endocr Dev. 2018;33:46-56
pubmed: 29886481
Eur J Endocrinol. 2018 Jul;179(1):59-71
pubmed: 29764907
Eur J Endocrinol. 2009 Nov;161(5):663-9
pubmed: 19734242
Horm Res Paediatr. 2019;92(1):1-14
pubmed: 31514194
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):E3331-9
pubmed: 23940366
Lancet Oncol. 2021 May;22(5):e196-e206
pubmed: 33845037
JAMA. 2017 Feb 28;317(8):814-824
pubmed: 28245323
J Clin Endocrinol Metab. 2014 Jun;99(6):2030-7
pubmed: 24606096
BMC Pediatr. 2008 Jun 20;8:25
pubmed: 18570650
Mol Cell Endocrinol. 2020 Dec 1;518:111003
pubmed: 32919021
Geroscience. 2017 Apr;39(2):147-160
pubmed: 28233247
Clin Chem Lab Med. 2011 Jul;49(7):1135-42
pubmed: 21627539
Cancer Drug Resist. 2019 Summer;2:827-846
pubmed: 32382711
J Mammary Gland Biol Neoplasia. 2013 Dec;18(3-4):277-89
pubmed: 24154546
J Clin Endocrinol Metab. 2011 Sep;96(9):2756-61
pubmed: 21715535
Exp Mol Med. 2019 Jan 7;51(1):1-13
pubmed: 30617282
J Clin Endocrinol Metab. 2002 Jul;87(7):3136-41
pubmed: 12107213
J Clin Endocrinol Metab. 2016 Nov;101(11):3888-3921
pubmed: 27736313
Eur J Endocrinol. 2013 Mar 15;168(4):565-73
pubmed: 23359434
Rev Endocr Metab Disord. 2021 Mar;22(1):59-70
pubmed: 33047268
J Pediatr Hematol Oncol. 2011 Aug;33(6):e231-8
pubmed: 21792029
Horm Res Paediatr. 2016;86(6):361-397
pubmed: 27884013
J Clin Endocrinol Metab. 2018 Aug 1;103(8):2794-2801
pubmed: 29982555
Lancet Diabetes Endocrinol. 2020 Aug;8(8):683-692
pubmed: 32707116
J Clin Endocrinol Metab. 2007 Apr;92(4):1195-200
pubmed: 17409338
Eur J Endocrinol. 2016 Sep;175(3):181-90
pubmed: 27280374
Cells. 2020 Nov 09;9(11):
pubmed: 33182502